SU 5416

Biological Activity for SU 5416

Technical Data for SU 5416

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility for SU 5416

References for SU 5416

References are publications that support the biological activity of the product.

• Hempel C, Hoyer N, Staalso T, Kurtzhals J Effects of the vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor SU5416 on in vitro cultures of Plasmodium falciparum. Malar J, 2014;13(0):201. 2014 PMID: 24885283
• Lavoie J, Ormiston M, Perez-Iratxeta C, Courtman D, Jiang B, Ferrer E, Caruso P, Southwood M, Foster W, Morrell N, Stewart D Proteomic analysis implicates translationally controlled tumor protein as a novel mediator of occlusive vascular remodeling in pulmonary arterial hypertension. Circulation, 2014;129(21):2125-35. 2014 PMID: 24657995
• Yuen T, Silbereis J, Griveau A, Chang S, Daneman R, Fancy S, Zahed H, Maltepe E, Rowitch D Oligodendrocyte-encoded HIF function couples postnatal myelination and white matter angiogenesis. Cell, 2014;158(2):383-96. 2014 PMID: 25018103
• Fong et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularisation, and growth of multiple tumor types. Cancer Res., 1999;59:99 PMID: 9892193
• Smolich et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-Kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood, 2001;97:1413 PMID: 11222388
• Mologni et al. Inhibition of RET tyrosine kinase by SU5416. J.Mol.Endocrinol., 2006;37:199 PMID: 17032739